(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
A quick recap of 'Stranger Things' Seasons 1-4, plus key episodes to rewatch before Volume 1 of the final season drops - 2Solid Propensities: Little Changes for a Superior Life
- 3David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- 4Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies
- 5Sound and Delightful: 12 Nutritious Smoothie Recipes
- Share your number one city visit transport that leaves a mark on the world wake up!
- Support Your Investment funds with These Individual accounting Thoughts
- 5 Wellbeing Applications Assist You With remaining Fit
- Finding Your Motivation: Moves toward a Satisfying Life
- Family Holiday spots
- BHP liable for 2015 Brazil mine disaster: UK court
- Figure out How to Adjust Your Handshake to Various Societies
- The Best Computer games for Multiplayer Fun
- 4 injured in shooting at North Carolina tree lighting ceremony
